More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.66B
EPS
-1.59
P/E ratio
--
Price to sales
17.45
Dividend yield
--
Beta
0.785875
Previous close
$37.09
Today's open
$37.07
Day's range
$35.34 - $37.39
52 week range
$10.38 - $40.60
show more
CEO
Bassil I. Dahiyat
Employees
260
Headquarters
Pasadena, CA
Exchange
NASDAQ Global Market
Shares outstanding
75039689
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell engager, in adults with rheumatoid arthritis. The data are being presented in a poster session at the American College of Rheumatology (ACR) Convergence 2026 conference in.
Business Wire • Nov 9, 2026

Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.
Investors Business Daily • Nov 5, 2026

Xencor Reports Third Quarter 2026 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026. “Xencor's lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a mono.
Business Wire • Nov 4, 2026

Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates
Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
Xencor stock catapulted Monday to a nearly four-year high, briefly breaking out on positive results in kidney cancer.
Investors Business Daily • Oct 26, 2026

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for planned late-stage development and expects to begin a registration-enabling study in 2027.
MarketBeat • Oct 26, 2026

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst
At the ESMO Congress 2026, Xencor Inc. (NASDAQ:XNCR) shared updated results from the Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC).
Benzinga • Oct 26, 2026

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript
Seeking Alpha • Oct 26, 2026

Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway
Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg, supporting advancement toward FDA Accelerated Approval discussions in 1H 2027 and a phase 3 trial by late 2027. The company is expanding XmAb819 into other ENPP3+ solid tumors and progressing XmAb942 in phase 2b for ulcerative colitis, with interim data expected by end of 2026.
Seeking Alpha • Oct 26, 2026

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comp.
Business Wire • Oct 25, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Xencor Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.